Piceatannol exhibits selective toxicity to multiple myeloma cells and influences the Wnt/ beta-catenin pathway.
Aberrant activation of Wnt/β-catenin signaling promotes development and progression of various malignant neoplasms. Recent studies observed that the Wnt pathway is constitutively active in myeloma cells and promotes an exaggerated proliferation. Thus, the Wnt signaling pathway might be an attractive therapeutic target for multiple myeloma. In this study, we identified piceatannol as an inhibitor of the Wnt/β-catenin pathway and as a potent inducer of apoptosis in myeloma cells. Interestingly, healthy cells remained mainly unaffected. These results reveal a significant selective induction of apoptosis by piceatannol and suggest a significant in vivo effect against multiple myeloma.
Department of Internal Medicine III, Center for Integrated Oncology (CIO), University Hospital Bonn, Bonn, Germany.
Frederic Carsten
FC
Schmeel
Leonard Christopher
LC
Schmeel
Young
Y
Kim
Ingo G H
IG
Schmidt-Wolf
D000818:Animals; D017209:Apoptosis; D002460:Cell Line; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002470:Cell Survival; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D020128:Inhibitory Concentration 50; D051379:Mice; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000378:metabolism; D011419:Propidium / Q000737:chemistry; D013267:Stilbenes / Q000627:therapeutic use*; D016896:Treatment Outcome; D051153:Wnt Proteins / Q000378:metabolism; D060449:Wnt Signaling Pathway / Q000187:drug effects*; D051176:beta Catenin / Q000378:metabolism*
D013267:Stilbenes; D051153:Wnt Proteins; D051176:beta Catenin; D011419:Propidium; C041525:3,3',4,5'-tetrahydroxystilbene
Wnt inhibitor; Wnt pathway; beta-catenin; immuno therapy; myeloma; signaling